Trials / Completed
CompletedNCT02092818
EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,316 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
In accordance with the regulatory guidance this registry has been designed to collect information about the long-term safety of Adempas in real clinical practice outside the regulated environment of a controlled clinical study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Riociguat (Adempas, BAY63-2521) | The decision on clinical management of the patient including the actual treatment duration will be determined solely by the physician not by the clinical study protocol (CSP) |
Timeline
- Start date
- 2014-05-31
- Primary completion
- 2018-03-31
- Completion
- 2018-06-29
- First posted
- 2014-03-20
- Last updated
- 2019-06-19
Locations
28 sites across 28 countries: Argentina, Australia, Austria, Belgium, Canada, Colombia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Norway, Portugal, Russia, Saudi Arabia, Slovakia, Spain, Sweden, Switzerland, Taiwan, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT02092818. Inclusion in this directory is not an endorsement.